Breaking News

Trials & Filings in Brief: Nov. 20, 2013

By Gil Roth | November 20, 2013

Advaxis, Amgen, Cornerstone CytRx, Daiichi Sankyo, Genzyme, Sanofi, Zealand

Phase II
Advaxis starts HPV cancer trial . . . read more

Amgen presents PCSK9 LDL results . . . read more

CytRx starts GBM trial . . . read more

Zealand begins danegaptide POC trial . . . read more

Phase III
Daiichi's edoxaban exceeds warfarin targets . . . read more

Health Canada approves Sanofi's Aubagio . . . read more

Cornerstone launches Bethkis for CF . . . read more
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials